| Entry |
|
|---|
| Name |
Imatinib (INN);
Glamox (TN) |
|---|
| Formula |
C29H31N7O
|
|---|
| Exact mass |
493.259
|
|---|
| Mol weight |
493.6027
|
|---|
| Structure |
|
|---|
| Simcomp |
|
|---|
| Class |
Antineoplastic
DG01918 Tyrosine kinase inhibitor
DG03161 BCR-ABL inhibitor
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
|
|---|
| Remark |
| Product (DG00710): | D01441<JP/US> |
|
|---|
| Efficacy |
Antineoplastic, Tyrosine kinase inhibitor |
|---|
| Target |
|
|---|
| Pathway |
|
|---|
| Metabolism |
Enzyme: CYP3A4 [HSA: 1576]
|
|---|
| Interaction |
|
|---|
| Structure map |
| map07045 | Antineoplastics - protein kinase inhibitors |
|
|---|
| Other map |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01E PROTEIN KINASE INHIBITORS
L01EA BCR-ABL tyrosine kinase inhibitors
L01EA01 Imatinib
D08066 Imatinib (INN)
Drug groups [BR:br08330]
Antineoplastic
DG01918 Tyrosine kinase inhibitor
DG03161 BCR-ABL inhibitor
DG00710 Imatinib
D08066 Imatinib
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
DG00710 Imatinib
D08066 Imatinib
Target-based classification of drugs [BR:br08310]
Protein kinases
Receptor tyrosine kinases (RTK)
PDGFR family
FIP1L1-PDGFRA
D08066 Imatinib (INN)
KIT (CD117)
D08066 Imatinib (INN)
Non-receptor tyrosine kinases
ABL family
BCR-ABL [HSA_VAR:25v1]
D08066 Imatinib (INN)
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D08066
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D08066
Drug groups [BR:br08330]
Antineoplastic
DG01918 Tyrosine kinase inhibitor
DG03161 BCR-ABL inhibitor
DG00710 Imatinib
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
DG00710 Imatinib
|
|---|
| Other DBs |
|
|---|
| KCF data |
ATOM 37
1 C8x C 29.6100 -16.8000
2 C8y C 29.6100 -15.4000
3 C8x C 28.4200 -14.7000
4 C8x C 27.1600 -15.4000
5 C8y C 27.1600 -16.8000
6 C8x C 28.4200 -17.5000
7 C5a C 25.9700 -17.5000
8 N1b N 24.7800 -16.8000
9 C8y C 23.5900 -17.5000
10 C8x C 22.3300 -16.8000
11 C8y C 21.1400 -17.5000
12 C8y C 21.1400 -18.9000
13 C8x C 22.3300 -19.6000
14 C8x C 23.5900 -18.9000
15 N1b N 19.9500 -16.8700
16 C8y C 18.6900 -17.5700
17 N5x N 17.5000 -16.8700
18 C8y C 16.3100 -17.5700
19 C8x C 16.3100 -18.9700
20 C8x C 17.5000 -19.6700
21 N5x N 18.6900 -18.9700
22 C8y C 15.0500 -16.8700
23 C8x C 15.0500 -15.4700
24 N5x N 13.8600 -14.7700
25 C8x C 12.6000 -15.4700
26 C8x C 12.6000 -16.8700
27 C8x C 13.8600 -17.5700
28 C1b C 30.8000 -14.7000
29 N1y N 32.0600 -15.4000
30 C1x C 32.0600 -16.8000
31 C1x C 33.2500 -17.5000
32 N1y N 34.4400 -16.8000
33 C1x C 34.4400 -15.4000
34 C1x C 33.2500 -14.7000
35 C1a C 35.7000 -17.5000
36 O5a O 25.9700 -18.9000
37 C1a C 19.9500 -19.6000
BOND 41
1 18 19 2
2 19 20 1
3 20 21 2
4 21 16 1
5 3 4 2
6 18 22 1
7 4 5 1
8 5 6 2
9 6 1 1
10 9 10 2
11 10 11 1
12 22 23 2
13 23 24 1
14 24 25 2
15 25 26 1
16 26 27 2
17 27 22 1
18 11 12 2
19 2 28 1
20 12 13 1
21 28 29 1
22 13 14 2
23 14 9 1
24 11 15 1
25 5 7 1
26 29 30 1
27 30 31 1
28 31 32 1
29 32 33 1
30 33 34 1
31 34 29 1
32 15 16 1
33 32 35 1
34 7 36 2
35 7 8 1
36 12 37 1
37 1 2 2
38 8 9 1
39 2 3 1
40 16 17 2
41 17 18 1
|
|---|
